Structure-based identification of inhibitors disrupting the CD2-CD58 interactions.

Area of Science:

• Immunology
• Computational Chemistry
• Drug Discovery

Background:

• The immune system relies on complex molecular interactions for infection defense.
• T-cell recognition by antigen-presenting cells (APCs) is initiated by CD2-CD58 interactions.
• Inhibiting CD2-CD58 interactions presents a therapeutic opportunity for managing aberrant immune responses.

Purpose of the Study:

• To identify novel small molecules that inhibit CD2-CD58 interactions.
• To explore the therapeutic potential of targeting T-cell-APC recognition.

Main Methods:

• Classical molecular dynamics (MD) simulations to identify key CD58 residues.
• Pharmacophore mapping and virtual screening of ~300,000 compounds.
• ADME screening, molecular docking, and short MD simulations for hit validation.

Main Results:

• MD simulations identified crucial CD58 residues for CD2 binding.
• Virtual screening yielded 15 compounds with significant binding energy (< -50 kcal/mol).
• Eight compounds demonstrated high binding affinity to CD58, suitable for in vitro testing.

Conclusions:

• Novel inhibitors of CD2-CD58 interaction were identified through computational methods.
• The identified compounds represent promising candidates for therapeutic intervention in immune-related diseases.
• Further in vitro validation is recommended for the top eight compounds.